0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Clinicopathologic Reports, Case Reports, and Small Case Series |

Bilateral Simultaneous Anterior Ischemic Optic Neuropathy in a Young, Healthy Man FREE

Mitchell J. Goff, MD; John B. Kerrison, MD
[+] Author Affiliations

Section Editor: W. Richard Green, MD

More Author Information
Arch Ophthalmol. 2003;121(11):1652-1653. doi:10.1001/archopht.121.11.1652.
Text Size: A A A
Published online

While a small cup-disc ratio is the predominant risk factor in the development of anterior ischemic optic neuropathy (AION), other hemodynamic factors likely play a part in its occurrence. A case of bilateral AION in a young, healthy man is presented, in whom multiple factors may have contributed to vision loss.

A 42-year-old male pilot underwent myopic photorefractive keratectomy(−2.00 OD and −2.25 OS). Five weeks postoperatively, he began taking 0.5% timolol, 2 times per day in each eye, for persistent steroid-induced ocular hypertension (30 mmHg). Three days later, he commenced a 5-day backpacking trek, ascending from sea level to an elevation of 6000 ft. On the third day of hiking, he experienced headaches and bilateral, intermittent photopsias, which he described as slow-moving streaks of light in his inferior field of vision, lasting for several minutes. While his headaches subsided after completion of the hike, his photopsias persisted for 8 days, at which time, he underwent ophthalmic examination. His medications included timolol, 2 times per day in each eye, and 0.1% fluorometholone acetate, 3 times per day in each eye. He did not have a significant medical history, history of migraine, or ocular history.

On examination, his visual acuity without correction was 20/20 OU. Intraocular pressure was 16 mmHg OD and 17 mmHg OS. He had no relative afferent pupillary defect. Slitlamp biomicroscopy disclosed a well-healed corneal ablation zone in each eye. Ophthalmoscopy revealed bilateral optic nerve swelling, with a cup-disc ratio of 0.1 OU (Figure 1).Automated static perimetry disclosed bilateral inferior altitudinal visual field defects (Figure 2). His blood pressure at that time (118/70 mmHg) was unchanged in comparison with his blood pressure prior to the initiation of timolol (114/70 mmHg). Findings on magnetic resonance imaging of the brain and orbits with contrast and lumbar puncture, including opening pressure, were normal. Results of laboratory evaluation including prothrombin time, partial thromboplastin time, international normalized ratio (for anticoagulant monitoring), protein C and S, viscosity, factor V Leiden, homocysteine levels, antithrombin III activity, anticardiolipin and lupus anticoagulant, erythrocyte sedimentation rate, C-reactive protein, antinuclear antibody, rapid plasma reagin, microhemagglutination-Trepona pallidum, Lyme antibody, complete blood cell count, and angiotensin-converting enzyme, were normal. A low positive antibody titer of Bartonella henselae and B quintana (immunoglobulin G, 1:64; immunoglobulin M, <1:20 for each antibody) by enzyme-linked immunosorbent assay was not confirmed by the more clinically validated immunofluorescent assay.

Place holder to copy figure label and caption
Figure 1.

Fundus photographs demonstrate bilateral optic nerve edema.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.

Automated static perimetry. Initial examination (top row) and 4 months after onset of symptoms (bottom row).

Graphic Jump Location

The patient was diagnosed as having bilateral AION and began taking aspirin, 325 mg/d, and 0.2% bromonidine tartrate, 3 times per day in each eye. Four months later, he had an uncorrected visual acuity of 20/20 OU, mild inferior visual field defects (Figure 2), and superior segmental disc pallor.

This patient's signs and symptoms, work-up findings, course, and outcome are consistent with a diagnosis of AION. Multiple factors are likely to have played a role, each involving hemodynamic alterations at the optic nerve head. This patient had a small cup-disc ratio, a disc configuration regarded as a risk factor for anterior ischemic optic neuropathy.1,2 However, the bilateral, simultaneous onset suggests that additional risk factors may have played a role. The effects of systemically absorbed topical beta blockers include decreased cardiac output, heart rate, and blood pressure, as well as adverse effects of bronchospasm and arrhythmias.3 Hayreh et al4 suggest that, due to their potential ability to limit autoregulation during nocturnal hypotension, the use of topical beta blockers may be a risk factor for nonarteritic AION in susceptible individuals. Various compensatory adaptations to exertion and altitude occur, including increased heart rate and cardiac output. The recent introduction of a beta blocker may have impaired these critical autoregulatory mechanisms, leading to inadequate optic nerve head perfusion under these conditions. The transient headache while at a high altitude may have been another early manifestation of poor adaptation to altitude.

The development of bilateral AION in this patient was likely multifactorial. He had a "disc at risk, " underwent photorefractive keratectomy, and was subsequently exposed to multiple potentially contributing factors, including initiation of topical beta blocker medications followed by prolonged exertion at an elevated altitude, all of which might cause alterations in optic nerve head perfusion. While none of these factors individually may be regarded as causative for AION in this patient, their combined hemodynamic effect may have overwhelmed the autoregulatory capacity of the optic nerve vasculature, resulting in ischemia.

The authors have no relevant financial interest in this article.

The views are the authors and do not reflect the official policy of the Department of Defense or any other agency of the US government.

Corresponding author: John B. Kerrison, MD, Wilmer Eye Institute, Johns Hopkins Hospital, Maumenee B109, 600 N Wolfe St, Baltimore, MD 21287(e-mail: jkerrisl@jhmi.edu).

Burde  RM Optic disk risk factors for nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol. 1993;116759- 764
PubMed
Beck  RWSavino  PJRepka  MX  et al.  Optic disc structure in anterior ischemic optic neuropathy. Ophthalmology. 1984;911334- 1337
PubMed Link to Article
Nelson  WLFraundfelder  FTSills  JMArrowsmith  JBDuritsky  JN Adverse respiratory and cardiovascular events attributed to timolol ophthalmic solution. Am J Ophthalmol. 1986;102606- 611
PubMed
Hayreh  SSPodhajsky  PAZimmerman  MB Beta blocker eyedrops and nocturnal arterial hypotension. Am J Ophthalmol. 1999;128301- 309
PubMed Link to Article

Figures

Place holder to copy figure label and caption
Figure 1.

Fundus photographs demonstrate bilateral optic nerve edema.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.

Automated static perimetry. Initial examination (top row) and 4 months after onset of symptoms (bottom row).

Graphic Jump Location

Tables

References

Burde  RM Optic disk risk factors for nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol. 1993;116759- 764
PubMed
Beck  RWSavino  PJRepka  MX  et al.  Optic disc structure in anterior ischemic optic neuropathy. Ophthalmology. 1984;911334- 1337
PubMed Link to Article
Nelson  WLFraundfelder  FTSills  JMArrowsmith  JBDuritsky  JN Adverse respiratory and cardiovascular events attributed to timolol ophthalmic solution. Am J Ophthalmol. 1986;102606- 611
PubMed
Hayreh  SSPodhajsky  PAZimmerman  MB Beta blocker eyedrops and nocturnal arterial hypotension. Am J Ophthalmol. 1999;128301- 309
PubMed Link to Article

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 1

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles